These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1535654)

  • 1. Growth factors in the pathogenesis of renovascular complications of diabetes mellitus.
    Woolf AS; Bosch RJ; Fine LG
    J Hypertens Suppl; 1992 Apr; 10(1):S11-6. PubMed ID: 1535654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts of renal hemodynamics in diabetes.
    Anderson S; Vora JP
    J Diabetes Complications; 1995; 9(4):304-7. PubMed ID: 8573753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of kidney injury by basic fibroblast growth factor or platelet-derived growth factor does not induce progressive diabetic nephropathy in the Goto Kakizaki model of non-insulin-dependent diabetes.
    Riley SG; Steadman R; Williams JD; Floege J; Phillips AO
    J Lab Clin Med; 1999 Sep; 134(3):304-12. PubMed ID: 10482316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II and its receptors in the diabetic kidney.
    Burns KD
    Am J Kidney Dis; 2000 Sep; 36(3):449-67. PubMed ID: 10977776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfiltration and diabetic nephropathy: is it the beginning? Or is it the end?
    Castellino P; Shohat J; DeFronzo RA
    Semin Nephrol; 1990 May; 10(3):228-41. PubMed ID: 2190280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis.
    Wang SN; Hirschberg R
    Am J Physiol Renal Physiol; 2000 Apr; 278(4):F554-60. PubMed ID: 10751215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal hypertrophy, growth factors, and nephropathy in diabetes mellitus.
    Schwieger J; Fine LG
    Semin Nephrol; 1990 May; 10(3):242-53. PubMed ID: 2190281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glomerular hyperfiltration in diabetic nephropathy].
    Ito O; Ito S
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():331-5. PubMed ID: 15999729
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin as a renal growth promoting factor.
    Wolf G
    Adv Exp Med Biol; 1995; 377():225-36. PubMed ID: 7484425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy.
    Arima S; Ito S
    Nephrol Dial Transplant; 2003 Oct; 18(10):1966-9. PubMed ID: 13679465
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes.
    Segev Y; Eshet R; Yakir O; Haim N; Phillip M; Landau D
    Diabetologia; 2007 Jun; 50(6):1327-34. PubMed ID: 17443310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms.
    Wolf G; Ziyadeh FN
    Am J Kidney Dis; 1997 Jan; 29(1):153-63. PubMed ID: 9002545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal injury from angiotensin II-mediated hypertension.
    Johnson RJ; Alpers CE; Yoshimura A; Lombardi D; Pritzl P; Floege J; Schwartz SM
    Hypertension; 1992 May; 19(5):464-74. PubMed ID: 1568765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The renal endothelium in diabetic nephropathy.
    Eleftheriadis T; Antoniadi G; Pissas G; Liakopoulos V; Stefanidis I
    Ren Fail; 2013; 35(4):592-9. PubMed ID: 23472883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving role of growth factors in the renal response to acute and chronic disease.
    Fine LG; Hammerman MR; Abboud HE
    J Am Soc Nephrol; 1992 Jan; 2(7):1163-70. PubMed ID: 1591357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of diabetic renal hypertrophy.
    Wolf G; Ziyadeh FN
    Kidney Int; 1999 Aug; 56(2):393-405. PubMed ID: 10432377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.
    Ichinose K; Maeshima Y; Yamamoto Y; Kitayama H; Takazawa Y; Hirokoshi K; Sugiyama H; Yamasaki Y; Eguchi K; Makino H
    Diabetes; 2005 Oct; 54(10):2891-903. PubMed ID: 16186390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic bilateral renal denervation attenuates renal injury in a transgenic rat model of diabetic nephropathy.
    Yao Y; Fomison-Nurse IC; Harrison JC; Walker RJ; Davis G; Sammut IA
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F251-62. PubMed ID: 24899056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies.
    Hilgers KF; Mann JF
    Kidney Blood Press Res; 1996; 19(5):254-62. PubMed ID: 8956237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.